Neuralstem spends US$3 mln on ischemic stroke treatment study

KUALA LUMPUR, Aug 2 (Bernama) -- Neuralstem Inc will allocate US$3 million (RM12.15 million) toward Phase 2 clinical trial evaluating neural stem cell candidate, NSI-566 as a potential treatment for ischemic stroke. (1US$ = RM4.05)



Ischemic stroke is the most common type of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke -- 87 per cent are ischemic strokes, a statement said.



Chief Scientific Officer of Neuralstem, Dr. Karl Johe said the Phase 2 study will be a randomized, double-blind, controlled study, based on the encouraging results from the open-label Phase 1 safety study.



“It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed,” he added.



The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on Aug 1 with Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, Dr. James Li managing the clinical trial.



--BERNAMA







HealthEdge


EXCLUSIVE

Pet Vaccination, Public Awareness And Surveillance Key Towards Rabies-free Southeast Asia - Experts

KUCHING, Dec 11 (Bernama) -- The goal of making Southeast Asia free from human rabies can be achieved through a total understanding of the disease, how it can be prevented and responsible pet ownership among communities, say experts.

read more ››

IN FOCUS

Pandangan rakyat Malaysia tentang peningkatan sasaran pemberian vaksin COVID-19 kepada 70 peratus.


UMSC: Pain Management

In Focus : UMSC Raya Open House 2018

In Focus: UMSC Consultant Speaks Erectile Dysfunction Precursor For Heart Disease Part 2

In Focus: UMSC Consultant Speaks Erectile Dysfunction Precursor For Heart Disease Part 1